Newsroom

April 6, 2026

What Makes Tasly Pharmaceuticals, Inc. a Strong Collaboration Partner

Tasly Pharmaceuticals, Inc. (TPI) is a U.S.-based biopharmaceutical company focused on advancing botanical drug development through scientific research, clinical evaluation, and global collaboration. TPI works with strategic partners across the pharmaceutical, biotechnology, and healthcare sectors to support the development of innovative therapeutic solutions for patients in the United States and international markets. TPI’s development approach […]

News
March 16, 2023

Tasly Pharmaceuticals, Inc. Participated in Trade Winds ASEAN Mission and Business Forum (2023)

Tasly Pharmaceuticals, Inc. Participated in U.S. Government-Led Trade Mission to Support Regulatory Engagement and Global Development Strategy Rockville, MD – March 16, 2023 – Tasly Pharmaceuticals, Inc. (“TPI”), a Maryland-based biopharmaceutical company, participated in the Trade Winds ASEAN Mission and Business Forum held March 13–15, 2023, in Bangkok, Thailand. The Trade Winds program, organized by […]

News
October 17, 2022

Tasly Pharmaceuticals to Exhibit at BioJapan (2022)

Tasly Pharmaceuticals, Inc. Participated in Maryland Delegation at Asia’s Premier Biotechnology Partnering Event Rockville, MD – October 17, 2022 – Tasly Pharmaceuticals, Inc. (“TPI”), a Maryland-based biopharmaceutical company, participated as an exhibitor at BioJapan 2022, an international partnering conference for the biotechnology and pharmaceutical industries, held in Yokohama, Japan, from October 12 to 14, 2022. […]

News
May 17, 2018

Tasly Pharmaceuticals, Inc. Presented Phase III Clinical Data for T89 (Dantonic®) at ACC 2018

ROCKVILLE, MD – Tasly Pharmaceuticals, Inc. announced the presentation of Phase III clinical trial results for its investigational botanical drug candidate T89 (Dantonic®) at the American College of Cardiology (ACC) 67th Annual Scientific Session held on March 12, 2018, in Orlando, Florida. The multi-center, randomized, double-blind, placebo-controlled Phase III study evaluated T89 in patients with […]

News